Information for the public
About this information
This information explains the evidence summary about the unlicensed and off-label use of melatonin to improve sleep for children and young people (under the age of 18 years) with attention deficit hyperactivity disorder (ADHD). The evidence summary is an overview of the available information about this medicine. It aims to help prescribers and patients, and their parents or carers if appropriate, when they are considering whether or not to use an unlicensed or off-label treatment. The summary does not contain recommendations from NICE on whether the medicine should be used.